A Peripheral CB1R Antagonist Increases Lipolysis, Oxygen Consumption Rate, and Markers of Beiging in 3T3-L1 Adipocytes Similar to RIM, Suggesting that Central Effects Can Be Avoided

With the increased prevalence of obesity and related co-morbidities, such as type 2 diabetes (T2D), worldwide, improvements in pharmacological treatments are necessary. The brain- and peripheral-cannabinoid receptor 1 (CB1R) antagonist rimonabant (RIM) has been shown to induce weight loss and improv...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Mol Sci
Main Authors: Paszkiewicz, Rebecca L., Bergman, Richard N., Santos, Roberta S., Frank, Aaron P., Woolcott, Orison O., Iyer, Malini S., Stefanovski, Darko, Clegg, Deborah J., Kabir, Morvarid
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7554772/
https://ncbi.nlm.nih.gov/pubmed/32927872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21186639
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares